STCube
STCube is a South Korea-based biotechnology company running 2 late-stage cancer trials of Nelmastobart in non-small-cell lung cancer and colorectal cancer.
Overview
STCube, based in Seoul, South Korea, is a biotechnology company. STCube (STCube Pharmaceuticals) develops immunotherapy drugs targeting novel immune checkpoints, with a lead focus on inhibiting BTN1A1 in cancer. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing Nelmastobart in non-small-cell lung cancer and colorectal cancer. The largest, NCT07306624 (Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer), plans to enrol 62 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyMultitude Therapeutics
Shares Colorectal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyAvistone Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMaia Biotechnology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyMBrace Therapeutics
Shares Colorectal cancer, Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCivaTech Oncology
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyKrystal Biotech
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanymAbxience Research S.L.
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.
- CompanyCelltrion
Shares Non-small-cell lung cancer and the tag ctgov-sponsor.